Breast Cancer. Key Words. Breast cancer Estrogen Estrone sulfate Steroid sulfatase Sulfatase inhibitor
|
|
- Virgil Robinson
- 6 years ago
- Views:
Transcription
1 The Oncologist Breast Cancer Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer SUSANNAH J. STANWAY, a PATRICK DELAVAULT, b ATUL PUROHIT, a L. W. LAWRENCE WOO, c CHRISTOPHE THURIEAU, b BARRY V. L. POTTER, c MICHAEL J. REED a a Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College, St. Mary s Hospital, London, United Kingdom; b Ipsen, Institute Henri Beaufour, Les Ulis, France; c Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Bath, United Kingdom Key Words. Breast cancer Estrogen Estrone sulfate Steroid sulfatase Sulfatase inhibitor LEARNING OBJECTIVES After completing this course, the reader will be able to: 1. Discuss the role of steroid sulfatase in regulating estrogen production in postmenopausal women. 2. Describe the potential of steroid sulfatase inhibition in cancer therapy. 3. Discuss a potential new endocrine therapy for patients progressing on aromatase. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit at CME.TheOncologist.com ABSTRACT Inhibitors of steroid sulfatase are being developed as a novel therapy for hormone-dependent breast cancer in postmenopausal women. Data suggest that steroid sulfatase (STS) activity is much higher than aromatase activity in breast tumors and high levels of STS mrna expression in tumors are associated with a poor prognosis. STS hydrolyzes steroid sulfates, such as estrone sulfate and dehydroepiandrosterone sulfate (DHEAS), to estrone and DHEA, which can be converted to steroids with potent estrogenic properties, that is, estradiol and androstenediol, respectively. Several potent irreversible STS inhibitors have now been identified, including STX64 (BN83495), a tricyclic sulfamate ester. This drug recently completed the first-ever trial of this new type of therapy in postmenopausal women with estrogen receptor positive metastatic breast cancer. STX64, tested at 5-mg and 20-mg doses, was able to almost completely block STS activity in peripheral blood lymphocytes and tumor tissues. Inhibition of STS activity was associated with significant reductions in serum concentrations of androstenediol and estrogens. Unexpectedly, serum androstenedione concentrations also decreased by up to 86%, showing that this steroid, which is the main substrate for the aromatase in postmenopausal women, is derived mainly from the peripheral conversion of DHEAS. Of eight patients who completed therapy, five showed evidence of stable disease for up to 7.0 months. This new endocrine therapy offers considerable potential for the treatment of hormone-dependent breast cancer in postmenopausal women. The Oncologist 2007;12: Disclosure of potential conflicts of interest is found at the end of this article. Correspondence: M. J. Reed, Ph.D., D.Sc., F.R.C. Path, Endocrinology and Metabolic Medicine, Imperial College, St. Mary s Hospital, London, W2 1NY, United Kingdom. Telephone: ; Fax: ; m.reed@imperial.ac.uk Received October 4, 2006; accepted for publication February 8, AlphaMed Press /2007/$30.00/0 doi: /theoncologist The Oncologist 2007;12:
2 Stanway, Delavault, Purohit et al. 371 INTRODUCTION Breast cancer continues to be a major cause of death in European and American women, occurring most frequently in postmenopausal women. In this group of women, the production of estrogens, which have a crucial role in supporting the development and growth of breast tumors, is greatly reduced following the cessation of ovarian function. However, estrogens continue to be produced at a low level in postmenopausal women, mainly from the peripheral conversion of androstenedione to estrone. This reaction is mediated by the aromatase complex and takes place mainly in adipose tissue but also in normal and malignant breast tissues [1, 2]. In view of the important role that estrogens have in breast cancer, current therapies in postmenopausal women aim to either block its interaction with the estrogen receptor (ER), by use of an antiestrogen such as tamoxifen or an ER downregulator, or inhibit the conversion of androstenedione to estrone with an aromatase inhibitor (e.g., letrozole, anastrozole, exemestane) [3, 4]. Over the last decade, considerable research has been carried out into the synthesis of steroids with estrogenic properties, which has suggested that, in addition to aromatase, another enzyme, steroid sulfatase (STS), may also have a crucial role in regulating the synthesis of estrogenic steroids in breast cancer [5]. Potent STS inhibitors have now been developed, paving the way to use this new type of therapy for breast cancer. STS STS is the enzyme responsible for the hydrolysis of steroid sulfates to their unconjugated, biologically active forms. After the synthesis of estrone from androstenedione by aromatase, much of it is rapidly sulfated to estrone sulfate (E1S) by a number of sulfotransferases that are widely distributed throughout the body [6]. Plasma concentrations of E1S are times higher than those of the unconjugated estrogens, estrone and estradiol [7]. Furthermore, the halflife of E1S in plasma (10 12 hours) is considerably longer than that for estrone and estradiol (20 30 minutes). E1S is therefore thought to act as a reservoir for the formation of active estrogens via the action of STS [8]. This enzyme converts E1S to estrone that is then reduced to the biologically active estrogen, estradiol, by 17 -HSD1, which is overexpressed in many breast tumors (Fig. 1). STS also acts on other steroid sulfates, including dehydroepiandrosterone sulfate (DHEAS), which is secreted in large amounts (up to 20 mg per day) by the adrenal cortex [9]. STS converts DHEAS to DHEA, which can be reduced to androstenediol by 17 -HSD1. Androstenediol, although an androgen, can bind to the ER and stimulate the growth of Figure 1. Pathways of steroidogenesis in postmenopausal women and site of action of STX64 (BN83495). Abbreviations: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate. hormone-dependent breast cancer cells in vitro and carcinogen-induced mammary tumors in rodents [10, 11]. Although its affinity for the ER is lower than that of estradiol, it has been suggested that, because of its much higher plasma and tissue concentrations, it may be equipotent to estradiol in postmenopausal women [12]. STS IN BREAST TUMORS Research carried out some years ago initially revealed that STS activity was detectable in most breast tumors examined. STS activity was found to be present at a considerably higher level than aromatase and aromatase activity was only detectable in about 60% of tumors [13, 14]. Recently STS mrna expression has been measured in breast tumors and shown to be at a much higher level than aromatase mrna expression [15]. Such studies also revealed that STS mrna expression is higher in malignant than in normal breast tissue. Several studies have suggested that high levels of STS mrna expression in breast tumors are associated with a poor prognosis, whereas aromatase or 17 - HSD1 expression had no prognostic value [16, 17]. Thus, with the advent of potent STS inhibitors, the measurement of breast tumor STS mrna expression may allow a patient enrichment strategy to be adopted to target patients who may particularly benefit from this therapy. STS INHIBITORS IN PROSTATE AND ENDOMETRIAL CANCERS Although STS inhibitors were primarily developed for breast cancer therapy, they may also have a therapeutic role
3 372 Steroid Sulfatase in other hormone-dependent cancers, such as those occurring in the prostate and endometrium. STS activity is present in prostatic tissue and in LNCaP cells, which were derived from prostatic cancer tissue [18, 19]. In men with prostate cancer, castration results in only a 50% reduction in prostatic tissue concentrations of dihydrotestosterone [20]. It is thought that the remaining contribution originates from adrenal androgens, such as DHEAS, by an intracrine process within the prostate. Furthermore, therapies that aim to reduce prostatic testosterone concentrations (e.g., luteinizing hormone releasing hormone agonists) do not reduce androstenediol concentrations. This androgen can activate a mutated form of the androgen receptor that is found in LNCaP cells and in many prostatic tumors [21]. Thus, inhibiting STS activity in men with prostate cancer may reduce not only the production of testosterone from DHEAS but also androstenediol. STS activity is increased in endometrial cancer tissue, so its inhibition may also have therapeutic potential, by reducing estrogen synthesis, in this hormone-dependent cancer [22]. STS INHIBITORS Several potent irreversible STS inhibitors have now been identified, all of which have as their active pharmacophore an aryl ring to which a sulfamate ester is attached. The structure of the first-generation STS inhibitor STX64 (BN83495, also known as 667 Coumate) is shown in Figure 2. STX64 was shown to be a potent STS inhibitor in rodents and blocked the ability of E1S to stimulate the growth of carcinogen-induced mammary tumors in ovariectomized rats [23]. Second-generation STS inhibitors, such as the steroid-based STX213 (Fig. 2), have now been developed, which inhibit STS activity in rodents, after the administration of a single dose, for a much longer period of time than STX64 [24, 25]. These STS inhibitors are orally active with a high level of bioavailability. This results from their binding to carbonic anhydrase II in erythrocytes after absorption, which enables them to transit the liver without undergoing first-pass inactivation [26]. CLINICAL USE OF STX64 The first-ever phase I trial of an STS inhibitor in postmenopausal women with locally advanced or metastatic breast cancer was recently reported by our group [27]. All the patients in the trial had been heavily pretreated with endocrine therapies (antiestrogen and/or aromatase inhibitors) while some had also received chemo- or radiotherapy. The primary endpoint of the study was to determine the dose of STX64 that inhibited STS activity by 90% in peripheral blood lymphocytes (PBLs), which have a high level of STS activity. Secondary endpoints included an examination of Figure 2. Molecular structures of STX64 and the secondgeneration steroid sulfatase inhibitor STX213. the ability of the drug to inhibit STS in tumor samples obtained from some patients and its effect on serum androstenediol and estrogen concentrations. The drug was administered orally, with patients receiving an initial dose (cycle 0) followed by 3 2 weekly cycles (cycles 1 3), with each cycle consisting of daily dosing for 5 days followed by 9 days off treatment. Patients in whom disease was stable at the end of cycle 3 were eligible for extended dosing. The drug was well tolerated, with only a few minor adverse events recorded. At a dose of 5 mg, 90% inhibition of STS activity in PBLs was achieved, and at the higher dose tested, 20 mg, almost complete inhibition of STS activity in PBLs and tumor tissue was detected (Fig. 3). Inhibition of STS activity was associated with significant reductions in serum androstenediol and estrogen concentrations. Unexpectedly, serum concentrations of androstenedione, the main substrate for aromatase in postmenopausal women, also decreased by up to 86%. This finding indicates that, in this group of women, androstenedione is derived mainly from the peripheral conversion of DHEAS and not, as previously thought, by direct secretion from the adrenal cortex. Of eight patients who completed cycles 0 3 of treatment, five showed evidence of stable disease for up to 7.0 months (range months) by the Response Evaluation Criteria in Solid Tumors. Importantly, all of the patients showing evidence of stable disease had previously been treated with, and progressed on, aromatase inhibitor therapy. The therapy was well tolerated, although all patients experienced some taste disturbance that was thought to be related to the formulation of the drug. SUMMARY Research into the pathophysiological role of STS in breast cancer led to the development of potent STS inhibitors, one of which has now been tested in a phase I trial of postmeno-
4 Stanway, Delavault, Purohit et al. 373 Figure 3. Inhibition of steroid sulfatase (STS) activity by STX64 in peripheral blood lymphocytes (PBLs) and tumor tissue, at 5-mg and 20-mg doses, in postmenopausal women with metastatic breast cancer. Median values for STS activity ( quartile range) are shown pre- and post-treatment. Comparison of STS activity before and after treatment was carried out using the Wilcoxon signed rank test (PBL STS, pre- versus posttreatment p.002; tumor STS p.016). Figures in parentheses represent the percentage of inhibition achieved. Adapted from Stanway SJ, Purohit A, Woo LWL et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12: pausal women with metastatic breast cancer. Results from that trial showed that STX64 almost completely blocked STS activity in PBLs and tumor tissues. Inhibition of STS activity was associated with significant decreases in not only serum concentrations of estrogens but also that of androstenediol, a steroid with potent estrogenic properties. Production of androstenediol is not blocked by aromatase inhibitors. Interestingly, this study also revealed that the main aromatase substrate in postmenopausal women, androstenedione, is derived mainly from DHEAS, rather than through direct secretion from the adrenal cortex. Although all patients had been pretreated with endocrine agents, and in some cases chemotherapy, five of the eight patients who completed cycles 0 3 of their treatment showed evidence of stable disease. These encouraging results will be followed by further trials in women with breast cancer to define the optimal biological dosing schedule. A patient enrichment strategy will also be employed taking advantage of measurements of STS mrna expression in tumors to select patients most likely to benefit from this new type of therapy. It will be particularly important to confirm that STS inhibitors can offer therapeutic benefit in patients who have progressed on antiestrogen and/or aromatase inhibitor therapies. It is anticipated that inhibition of STS activity will give rise to a significant clinical benefit and a favorable risk/benefit ratio in the setting of locally advanced or metastatic disease by offering a potential new additional option of endocrine therapy, initially in patients whose disease has progressed after prior aromatase inhibitor therapy. As this drug effectively blocks the production of androgens in addition to estrogens, it is also likely to be tested in other hormone-dependent tumors, such as prostate and endometrial cancer. ACKNOWLEDGMENTS This research was supported by Sterix, a member of the Ipsen Group. DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST P.D. and C.T. own stock in Ipsen. M.J.R., B.V.L.P., and A.P. have acted as consultants for and received support from Ipsen. M.J.R. and B.V.L.P. have served on the Board of Sterix. REFERENCES 1 Purohit A, Ghilchik MW, Duncan L et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 1995;80: Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis. Endocr Rev 1997;18: Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI Br J Cancer 1971; 25: Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348: Reed MJ, Purohit A, Woo LWL et al. Steroid sulfatase: Molecular biology, regulation, and inhibition. Endocr Rev 2005;26: Hobkirk R. Steroid sulfation. Trends Endocrinol Metab 1993;4: Ruder HJ, Loriaux L, Lipsett MB. Estrone sulfate: Production rate and metabolism in man. J Clin Invest 1972;51: Reed MJ, Purohit A, Woo LWL et al. The development of steroid sulfatase inhibitors. Endocr Relat Cancer 1996;3: Purohit A, Dauvois S, Parker MG et al. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. J Steroid Biochem Mol Biol 1994;50: Poulin R, Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in ZR-75 1 human breast cancer cell line. Cancer Res 1986;46: Dauvois S, Labrie F. Androstenedione and androst-5-ene-3,17 -diol
5 374 Steroid Sulfatase stimulate DMBA-induced rat mammary tumors role of aromatase. Breast Cancer Res Treat 1989;13: Spinola PG, Marchetti B, Labrie F. Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors. Breast Cancer Res Treat 1986;8: James VHT, McNeill JM, Lai LC et al. Aromatase activity in normal breast and breast tumor tissue: In vivo and in vitro studies. Steroids 1987;50: Tilson-Mallett N, Santner SJ, Feil PD et al. Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab 1983;57: Utsumi T, Yoshimura N, Takeuchi S et al. Elevated steroid sulfatase expression in breast cancers. J Steroid Biochem Mol Biol 2000;73: Utsumi T, Yoshimura N, Takeuchi S et al. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 1999;59: Miyoshi Y, Ando A, Hasegawa S et al. High expression of steroid sulfatase mrna predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 2003;9: Farnsworth WE. Human prostatic dehydroepiandrosterone sulfate sulfatase. Steroids 1973;21: Selcer KW, Kabler H, Sarap J et al. Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells. Steroids 2002;67: Titus MA, Schell MJ, Lih FB et al. Testosterone and dihydrotestesterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11: Mizokami A, Koh E, Fujita H et al. The adrenal androgen androstenediol is present in prostate tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64: Yamamoto T, Kitawaki J, Urabe M et al. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993;44: Purohit A, Woo LWL, Potter BVL et al. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 2000;60: Fischer DS, Chander SK, Woo LWL et al. Novel D-ring modified steroid derivatives as potent, non-estrogenic steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 2003;84: Foster PA, Newman SP, Chander SK et al. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 2006;12: Ho YT, Purohit A, Vicker N et al. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun 2003;305: Stanway SJ, Purohit A, Woo LWL et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:
Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer
Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer S.J. STANWAY 1, C. PALMIERI 2, F.Z. STANCZYK 3, E.J. FOLKERD
More informationTHE PRODUCTION OF both estrogen and progesterone
13-7227/8/$15./ Endocrinology 149(8):435 442 Printed in U.S.A. Copyright 28 by The Endocrine Society doi: 1.121/en.28-223 The Use of Steroid Sulfatase Inhibitors as a Novel Therapeutic Strategy Against
More informationSynthesis of sex steroids
Synthesis of sex steroids CH 3 NAD(P)H NAD(P)+ Dehidroepiandroszteron Androszténdion 17- -hidroxiszteroid dehidrogenáz CH 3 dehydroepiandrosterone Dehidroepiandroszteron (DHEA) 3SDH Koleszterin CH 3 aromatase
More informationReproductive. Estrone sulfate Analyte Information
Reproductive Estrone sulfate Analyte Information - 1 - Estrone sulfate Introduction Estrone sulfate (E1-S) is a sulfate derivative of estrone, and is the most abundant form of circulating estrogens in
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationLecture 10: Hormonal agents
Lecture 10: Hormonal agents The survival and proliferation (growth) of some cancer cells is dependent on the action of steroid hormones. Early stage breast cancer and early stage prostate cancer are the
More informationSEVERAL CLASSES OF endocrine agents that antagonize
REVIEW ARTICLE Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer By Paul E. Goss and Kathrin Strasser SEVERAL CLASSES OF endocrine agents that antagonize the effects of estrogen are
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationReproductive. Estradiol Analyte Information
Reproductive Estradiol Analyte Information - 1 - Estradiol Introduction Estradiol (E2 or 17β-estradiol) is the major estrogen in humans. Although it is often called the "female" hormone, it is also present
More informationBIOSYNTHESIS OF STEROID HORMONES
BIOSYNTHESIS OF STEROID HORMONES Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI sw/steroidrepro/inter/08 1 STEROID HORMONES Progestins (21 C) Glucocorticoids (21 C) Mineralocorticoids
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationVVA : new therapeutic options? BMS october 2017 A Pintiaux
VVA : new therapeutic options? BMS october 2017 A Pintiaux Disclosures Member of the european board of TEVA without personal gain No conflict of interest for this presentation VVA Vulvar and vaginal atrophy
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More information- ASCO ASCO. American Society of Clinical Oncology( VEGF( Vascular Endothelial Growth Factor) (angiogenesis) ASCO 2005
2005 5 24 () - ASC2005 - twatanab@oncoloplan.com / http://www.oncoloplan.com ASC American Society of Clinical ncology( ) 412005 5 13 17 3 5000 ASC 2005 bevacizumab / trastuzumab / mab monoclonal antibody
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationR R Tekmal 1, N Kirma 1, K Gill 1 and K Fowler 2. Abstract. Introduction. Endocrine-Related Cancer (1999)
Endocrine-Related Cancer (1999) 6 307-314 Aromatase overexpression and breast hyperplasia, an in vivo model continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationRadiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Chemotherapy Chemotherapy is a cancer
More informationAromatase inhibitors in breast cancer: Current and evolving roles
CURRENT DRUG THERAPY JOHN HILL, MD Department of Hematology and Medical Oncology, The Cleveland Clinic HALLE MOORE, MD Associate Professor, Department of Hematology and Clinical Oncology, The Cleveland
More informationReproductive DHEA Analyte Information
Reproductive DHEA Analyte Information - 1 - DHEA Introduction DHEA (dehydroepiandrosterone), together with other important steroid hormones such as testosterone, DHT (dihydrotestosterone) and androstenedione,
More informationReproductive Endocrinology
Reproductive Endocrinology Reproductive Endocrinology Hypothalamic hormones Gonadotropin releasing hormone (GnRH) - stimulate release of FSH = follicle stimulating hormone LH = luteinizing hormone from
More informationEndocrine Steroids 2. Signal transduction 3. Prostaglandins
Endocrine - 2 1. Steroids 2. Signal transduction 3. Prostaglandins Estrogen Menopause (pause in the menes) ["change of life" at about 50] - lack of estrogen. (Some hysterectomy or ovarian cancer surgeries
More informationDiabetes Mellitus and Breast Cancer
Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf
More informationMelatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone
1 Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone Cancer is a disease caused by out of control division of abnormal cells within a
More informationSuppression of 5 -androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells
Proc. Natl. Acad. Sci. USA Vol. 96, pp. 11173 11177, September 1999 Biochemistry Suppression of 5 -androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer
More informationUrinary Hormone Metabolites Adrenal
Test Name Result Range Urinary Androgens (μg/g Cr) DHEA (Urine) 503.87 H 9.01-93.80 Urinary Glucocorticoids (μg/g Cr) Total Cortisol (Urine) 18.50 8.73-28.52 Total Cortisone (Urine) 35.72 14.12-42.84 Cortisol/Cortisone
More informationMELATONIN SENSITIZES HUMAN BREAST CANCER CELLS TO IONIZING RADIATION
DEPARTMENT OF PHYSIOLOGY AND PHARMACOLOGY UNIVERSITY OF CANTABRIA, SANTANDER, SPAIN MELATONIN SENSITIZES HUMAN BREAST CANCER CELLS TO IONIZING RADIATION Crolin Alonso-González ANDROGENS ESTROGENS PERIPHERAL
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationCPY 605 ADVANCED ENDOCRINOLOGY
CPY 605 ADVANCED ENDOCRINOLOGY THE ADRENAL CORTEX PRESENTED BY WAINDIM NYIAMBAM YVONNE HS09A187 INTRODUCTION Two adrenal glands lie on top of each kidney. Each gland between 6 and 8g in weight is composed
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationDry Eye Workshop Tear Film Committee: Utility of endocrine markers in the diagnosis of dry eye syndromes
Dry Eye Workshop Tear Film Committee: Utility of endocrine markers in the diagnosis of dry eye syndromes 1. Objective To discuss the applicability of endocrine markers (i.e. levels of androgens, estrogens
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationReproductive physiology
Reproductive physiology Sex hormones: Androgens Estrogens Gestagens Learning objectives 86 (also 90) Sex Genetic sex Gonadal sex Phenotypic sex XY - XX chromosomes testes - ovaries external features Tha
More informationAlternative Androgen Metabolism in Resistance to Aromatase Inhibitors by Matthew Joseph Sikora
Alternative Androgen Metabolism in Resistance to Aromatase Inhibitors by Matthew Joseph Sikora A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationThe selective estrogen enzyme modulators in breast cancer: a review
Biochimica et Biophysica Acta 1654 (2004) 123 143 www.bba-direct.com Review The selective estrogen enzyme modulators in breast cancer: a review Jorge R. Pasqualini* Hormones and Cancer Research Unit, Institut
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationHormonal therapies for the adjuvant treatment of early breast cancer
Society for Endocrinology comments on the assessment report for the National Institute for Health and Clinical Excellence Appraisal of Hormonal therapies for the adjuvant treatment of early breast cancer
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationSPRMs, androgens and breast cancer
SPRMs, androgens and breast cancer Dr Joëlle Desreux BMS 04/06/2016 WHI : the nuclear explosion Looking for the perfect menopause treatment Hot flushes relieve Osteoporosis prevention Cardio-vascular health
More informationNew Development in Intracrinology of Breast Carcinoma
Breast Cancer Vol. 13 No. 2 April 2006 Review Article New Development in Intracrinology of Breast Carcinoma Hironobu Sasano, Takashi Suzuki, Taisuke Nakata, and Takuya Moriya Departments of Pathology,
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationSUPPLEMENTARY APPENDIX. COU-AA-301 enrolled men with pathologically confirmed mcrpc who had received previous
SUPPLEMENTARY APPENDIX Methods Subjects COUAA30 enrolled men with pathologically confirmed mcrpc who had received previous treatment with docetaxel chemotherapy and had documented PSA progression according
More informationBioidentical Hormones: Just the Facts
Bioidentical Hormones: Just the Facts Melissa McNeil, MD, MPH Professor of Medicine and Obstetrics, Gynecology and Reproductive Sciences Chief, Section of Women s Health University of Pittsburgh Disclosures!
More informationPRASTOVA SR Tablets (Dehydroepiandrosterone)
Published on: 31 Dec 2015 PRASTOVA SR Tablets (Dehydroepiandrosterone) Composition Each film-coated sustained release tablet contains: Dehydroepiandrosterone 75 mg (Micronized) Dosage Form Tablets for
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationEffect of CGS on ovarian aromatase and gonadotropin levels in the rat
Breast Cancer Research and Treatment 48: 45 51, 1998. 1998 Kluwer Academic Publishers. Printed in the Netherlands. Report Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat S.
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationAdrenal Stress Profile (Saliva)
Adrenal Stress Profile (Saliva) Ireland Cortisol Levels Sample 1 Post Awakening Sample 2 (+ 4-5 Hours) Sample 3 (+ 4-5 Hours) Sample 4 (Prior to Sleep) 11.42 2.10 1.60 0.47 Sum of Cortisol 15.590 DHEA
More informationEstrogens & Antiestrogens
Estrogens & Antiestrogens Menstrual cycle... Changes and hormonal events Natural estrogens: Estadiol >> Estrone > Estriol Ineffective orally Synthesis: From cholesterol ; role of aromatase enzyme in converting
More informationOne Day Hormone Check
One Day Hormone Check DOB: Sex: F MRN: Order Number: Completed: Received: Collected: Salivary Hormone Results Estradiol pmol/l >3330.0 Testosterone pmol/l
More informationDRIED URINE -INTEGRATIVE MEDICINE
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationNatural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
More informationReproductive System (Hormone Function) Physiology Department Medical School, University of Sumatera Utara
Reproductive System (Hormone Function) Physiology Department Medical School, University of Sumatera Utara 1 Endocrine Control: Three Levels of Integration Hormones of the hypothalamic-anterior pituitary
More informationEndocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre
Endocrine-Related Cancer (2006) 13 251 255 Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre K L Cheung, R Owers
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationCh 11: Endocrine System
Ch 11: Endocrine System SLOs Describe the chemical nature of hormones and define the terms proand prepro-hormone. Explain mechanism of action of steroid and thyroid hormones Create chart to distinguish
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationHormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive
Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive breast cancer Issued: November 2006 guidance.nice.org.uk/ta112 NICE 2006 Contents 1 Guidance... 3 2 Clinical need and practice...
More informationEstrogen (ER) receptor biology: Implications for HRT? Dr. Christoph A. Meier Endocrine Unit University Hospital Geneva
Estrogen (ER) receptor biology: Implications for HRT? Dr. Christoph A. Meier Endocrine Unit University Hospital Geneva Estrogens prevent postmenopausal bone-loss HRT & osteoporosis bip & estrogen bip
More informationCitation for published version (APA): van Kruchten, M. (2015). Molecular imaging of estrogen receptors [Groningen]: University of Groningen
University of Groningen Molecular imaging of estrogen receptors van Kruchten, Michel IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationSecretion of Unconjugated Androgens and Estrogens by the
Secretion of Unconjugated Androgens and Estrogens by the Normal and Abnormal Human Testis before and after Human Chorionic Gonadotropin R. L. WEINSTEIN, R. P. KELCH, M. R. JENNER, S. L. KAPLAN, and M.
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationBreast Cancer Risk in Patients Using Hormonal Contraception
Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation
More informationClinical Oncology - Science in focus - Editorial. Understanding oestrogen receptor function in breast cancer, and its interaction with the
Clinical Oncology - Science in focus - Editorial TITLE: Understanding oestrogen receptor function in breast cancer, and its interaction with the progesterone receptor. New preclinical findings and their
More informationMICRO SAMPLE ASSAYS Result Range Units
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationA Layperson's Guide to Endocrine (Hormone) Therapy
A Layperson's Guide to Endocrine (Hormone) Therapy What we will cover What is the endocrine system Basic definition of endocrine therapy Classes of endocrine drugs How you can utilise endocrine therapy
More informationIntracrine Androgens Enhance Decidualization and Modulate Expression of Human
Intracrine Androgens Enhance Decidualization and Modulate Expression of Human Endometrial Receptivity Genes. Authors: Douglas A Gibson 1, Ioannis Simitsidellis 1, Fiona L Cousins 1*, Hilary O.D. Critchley
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationCONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108
AD Award Number: W81XWH-06-1-0778 TITLE: Dietary Fat, Eicosanoids and Breast Cancer Risk PRINCIPAL INVESTIGATOR: Lindsay Orr CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108 REPORT DATE:
More informationThe menstrual cycle. François Pralong
The menstrual cycle François Pralong Services d Endocrinologie, Diabétologie et Métabolisme, Hôpitaux Universitaires de Genève et Lausanne Centre des Maladies CardioVasculaires et Métaboliques, Lausanne
More informationThe menstrual Cycle. François Pralong
The menstrual Cycle François Pralong Services d Endocrinologie, Diabétologie et Métabolisme, Hôpitaux Universitaires de Genève et Lausanne Centre des Maladies CardioVasculaires et Métaboliques, Lausanne
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationMapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD
Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD The University of Athens Medical School Dept of Clinical Therapeutics Prostate Cancer Evolution Chemotherapy
More informationGONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
original paper Haematologica 1994; 79:141-147 GONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA Fiorina Giona*, Luciana Annino*, Paola Donato, Michele
More information